<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03630315</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-0046</org_study_id>
    <nct_id>NCT03630315</nct_id>
  </id_info>
  <brief_title>CLN-0046: Treatment of AMD Subjects With OTX-TKI</brief_title>
  <official_title>A Phase 1 Open-Label, Dose Escalation Study of OTX-TKI for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocular Therapeutix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability and efficacy of OTX-TKI for intravitreal use, in&#xD;
      subjects who have neovascular age-related macular degeneration (AMD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center, dose escalation, Phase 1, safety, tolerability and efficacy study to evaluate&#xD;
      three dose groups of the OTX-TKI implant to treat subjects with a diagnosis of primary&#xD;
      subfoveal neovascularization secondary to AMD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events for each subject</measure>
    <time_frame>9 months</time_frame>
    <description>All adverse events from screening through end of study will be captured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the Maximum Tolerated Dose of the OTX-TKI injection</measure>
    <time_frame>9 months</time_frame>
    <description>A Central Reading Center will evaluate multiple imaging modalities to confirm evidence of biological activity for subjects that have been treated with the OTX-TKI injection. If all subjects tolerate lower dosages, additional subjects will be treated at higher dosages. All data will be evaluated by the DSMC who, in concert with the Medical Monitor, will determine the Maximally Tolerated Dose.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (Low Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a low dose of OTX-TKI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Middle Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a middle dose of OTX-TKI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (High Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a high dose of OTX-TKI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (Anti-VEGF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive OTX-TKI plus a single anti-VEGF injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (High Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a high dose of OTX-TKI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (Anti-VEGF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive OTX-TKI plus a single anti-VEGF injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTX-TKI</intervention_name>
    <description>OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).</description>
    <arm_group_label>Cohort 1 (Low Dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTX-TKI</intervention_name>
    <description>OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).</description>
    <arm_group_label>Cohort 2 (Middle Dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTX-TKI</intervention_name>
    <description>OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).</description>
    <arm_group_label>Cohort 3 (High Dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTX-TKI</intervention_name>
    <description>OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).</description>
    <arm_group_label>Cohort 3 (Anti-VEGF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-VEGF</intervention_name>
    <description>Standard of care therapy used to block vascular endothelial growth factor</description>
    <arm_group_label>Cohort 3 (Anti-VEGF)</arm_group_label>
    <other_name>aflibercept</other_name>
    <other_name>bevacizumab</other_name>
    <other_name>ranibizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTX-TKI</intervention_name>
    <description>OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).</description>
    <arm_group_label>Cohort 4 (Anti-VEGF)</arm_group_label>
    <arm_group_label>Cohort 4 (High Dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-VEGF</intervention_name>
    <description>Standard of care therapy used to block vascular endothelial growth factor</description>
    <arm_group_label>Cohort 4 (Anti-VEGF)</arm_group_label>
    <other_name>aflibercept</other_name>
    <other_name>bevacizumab</other_name>
    <other_name>ranibizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are at least 50 years of age&#xD;
&#xD;
          -  Are eligible for standard therapy&#xD;
&#xD;
          -  Have active primary CNVM secondary to AMD, either newly diagnosed or previously&#xD;
             treated with documented response to anti-VEGF therapy in the study eye [primary&#xD;
             subfoveal CNV secondary to AMD including juxtafoveal lesions that affect the fovea]&#xD;
             documented by FA and SD-OCT&#xD;
&#xD;
          -  Are female who is postmenopausal for at least 12 months prior to screening or&#xD;
             surgically sterile; or male or female of childbearing potential willing to use two&#xD;
             forms of adequate contraception&#xD;
&#xD;
          -  Are able and willing to comply with all study requirements and visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have previous laser photocoagulation to the center of the fovea in the study eye&#xD;
&#xD;
          -  Have participated in any study involving an investigational drug either in the U.S. or&#xD;
             outside the U.S. within the past 30 days&#xD;
&#xD;
          -  Are an employee of the site that is directly involved in the management,&#xD;
             administration, or support of the study, or be an immediate family member of the same&#xD;
&#xD;
          -  Have a presence of a disease other than CNVM due to AMD in the study eye that could&#xD;
             affect vision or safety assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Project Manager</last_name>
    <phone>1-781-357-4000</phone>
    <email>clinicalaffairs@ocutx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Sydney</city>
        <state>Site 1</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutiux, Inc.</name>
      <address>
        <city>Sydney</city>
        <state>Site 2</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutiux, Inc.</name>
      <address>
        <city>Sydney</city>
        <state>Site 3</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Albury</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Project Manager</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocular Therapeutix, Inc.</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

